Carboprost Tromethamine

CHEMBL1237105 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
489.6 g/mol
LogP
Phase
4

The tromethamine salt of carboprost is administered intramuscularly to treat postpartum hemorrhage caused by uterine atony that has not responded to conventional management. As a prostaglandin F2α analog, it potently stimulates myometrial contractions. It is contraindicated in patients with active cardiac, pulmonary, renal, or hepatic disease.

น้ำหนักโมเลกุล

489.6000 g/mol

TPSA

185.00 Ų

กลไกการออกฤทธิ์

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCC[C@](C)(O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO

InChI

InChI=1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5-,14-12+;/t16-,17-,18+,19-,21+;/m1./s1

Molecular Formula

C25H47NO8

HBD / HBA

8 / 9

พันธะที่หมุนได้

15

อะตอมหนัก

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The tromethamine salt of carboprost is administered intramuscularly to treat postpartum hemorrhage caused by uterine atony that has not responded to conventional management. As a prostaglandin F2α analog, it potently stimulates myometrial contractions. It is contraindicated in patients with active cardiac, pulmonary, renal, or hepatic disease.

Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.

Yes, Carboprost Tromethamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237105. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5281074. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.